Index Falls Following Tariff Announcements
Key points
- The S & P 500 index fell 0.8 % on Monday, February 3, because investors responded to tariffs on major US trading partners, while waiting for key revenue and labor market data.
- After the stock of Goldman Sachs lowered the stock of vaccine manufacturers, modern stocks extended the loss released last week because of high costs and uncertain income prospects.
- The stock of Idexx laboratory has surged, the highest quarterly forecast for veterinarian diagnostic providers, and its partner animal group segment has been improved.
US President Donald Trump announced on the weekend that he will Tariffs imposed on imports Main trading partners from Canada, Mexico and China. However, because Trump announced that the tariffs on Mexico will be Delay for one monthEssence
Although international trade relations dominate headline news, New Trading Week It will also bring the income report from the main names such as Amazon (Amzn) And Google’s parents (Googl), And the labor market data released on Friday morning January work reportEssence
The S & P 500 Index lost 0.8 % on Monday. The Dow Jones Index has recovered from the higher losses in the morning, and then decreased by 0.3 %, while the weakness of the technology industry was decreased by 1.2 % in Nasdaq’s shares.
Modern shares (mRNA) Falling 7.3 % and lost the largest stock of all stocks in the 500 index. The loss of the decline on Monday extended the losses released in late last week. At that time, Goldman Sachs reduced the stock of biotechnology companies from “buying” to “neutral”. The downgrade was after the second time the vaccine manufacturer reduced its product revenue guidelines within six months, and the analysts believed that modern people’s sales trajectory of their respiratory vaccine business was limited. Goldman Sachs’s team also predicts that in view of the increase in operating costs, modern people can not go bankrupt until 2029, exceeding the company’s updated 2028 target.
Franklin Resources (Book) The stock fell 6.9 %, and some strong returns to the investment management company last week were high. Although the bottom line is excellent, the income has not yet reached estimates. Franklin reported that the decline in management assets (AUM) reflected the impact of the influence of net outflow. The Bank of America slightly raised its price goals for Franklin’s resource stocks to estimate the renewal revenue, but analysts maintain a “poor performance” rating of the stock.
Federal Express (FDXAfter Loop Capital reduced the stock of the transportation company from “buying” and reduced its goals, the stock fell by 6.6 %. With the announcement of cyclic analysts in the White House, cycle analysts have reduced the prospects of the entire US transportation department, and pointed out that new trade policies may impose pressure and increase prices.
Tesla (Tesla (TSLA) Due to the influence of investors’ balance of Trump’s tariff policy, the stock fell 5.2 %. Electric vehicles (EV) manufacturers can see the change in the global trade environment and the impact of potential retaliation of tariffs, especially considering Tesla’s exposure in the Chinese market and close connection with US presidential management. A report shows that the decline in the registration of Tesla cars in Norway and Sweden in January also caused people’s concerns about Europe’s views on the brand.
Idexx laboratory (IDXX) The stock of the stock on Monday in the Standard Purcera 500 Index was sticked. Previously, the veterinary health care products and service providers reported the sales and profits in the fourth quarter. The continuous growth of the company’s animal test products will help promote outstanding performance, especially in the field of partner animal group (CAG), IDExx provides diagnostic testing, laboratory services and platforms for managing veterinary practice.
Molina Medical Care (No) The stock increased by 4.8 %. The custody care company is preparing to release its quarterly income report after Wednesday. Analysts predict that Molina’s sales and profits will be significantly higher than their age compared to the same period last year, and pointed out that the company’s low -income groups may promote growth.
A large number of investment research analysts have raised the price target for ABBVIE (ABBV) After the revenue of the stock was released last week. Pharmaceutical company Estimation of income in the fourth quarterDue to its sales growth of Skyrizi and RinvoQ, and ABBVIE increased the long -term sales prospects of two drugs. On Monday, ABBVIE’s stock price rose 3.4 %.